Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Raman Singh sold 9,024 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $68.62, for a total transaction of $619,226.88. Following the completion of the transaction, the director owned 44,637 shares in the company, valued at approximately $3,062,990.94. This represents a 16.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Raman Singh also recently made the following trade(s):
- On Monday, September 14th, Raman Singh sold 8,468 shares of Liquidia stock. The stock was sold at an average price of $66.16, for a total transaction of $560,242.88.
Liquidia Stock Down 0.1%
Liquidia stock opened at $68.39 on Friday. Liquidia Corporation has a fifty-two week low of $21.15 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The firm has a 50 day moving average price of $76.40 and a 200 day moving average price of $60.45. The company has a market capitalization of $6.12 billion, a PE ratio of 49.92 and a beta of 0.53.
Hedge Funds Weigh In On Liquidia
A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. Covestor Ltd raised its stake in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. Globeflex Capital L P acquired a new position in shares of Liquidia during the 2nd quarter worth about $175,000. Nykredit A S purchased a new position in shares of Liquidia in the 2nd quarter valued at about $177,000. Hurley Capital LLC increased its holdings in shares of Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after acquiring an additional 3,040 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Liquidia by 7.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after acquiring an additional 422 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. Bank of America increased their price target on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Friday, July 17th. Needham & Company LLC upped their target price on shares of Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. BTIG Research increased their target price on shares of Liquidia from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $106.00 price target on shares of Liquidia in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Liquidia has an average rating of “Hold” and a consensus target price of $98.08.
Check Out Our Latest Report on LQDA
About Liquidia
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.
Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.
Further Reading
- Five stocks we like better than Liquidia
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
